PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award

Rhea-AI Filing Summary

PROKIDNEY CORP. director Brian JG Pereira received a grant of 135,000 director stock options as part of the company’s non-employee director compensation policy. The options have an exercise price of $1.81 per share, expire on May 28, 2036, and cover 135,000 shares of Class A common stock. According to the terms, the options will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting, and this grant brings his reported option holdings in this award to 135,000 options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pereira Brian JG

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director stock option (right to buy)	135,000	$0.00	--

Holdings After Transaction: Director stock option (right to buy) — 135,000 shares (Direct, null)

Footnotes (1)

1. These options were granted under the Issuer's non-employee director compensation policy. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

Key Figures

Options granted: 135,000 options Exercise price: $1.81 per share Underlying shares: 135,000 shares +1 more

4 metrics

Options granted 135,000 options Director stock option grant to Brian JG Pereira

Exercise price $1.81 per share Director stock option grant

Underlying shares 135,000 shares Class A Common Stock underlying the options

Expiration date May 28, 2036 Option term end date

Key Terms

Director stock option, non-employee director compensation policy, vest in full, Class A Common Stock

4 terms

Director stock option financial

"security_title: "Director stock option (right to buy)""

non-employee director compensation policy financial

"These options were granted under the Issuer's non-employee director compensation policy."

vest in full financial

"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pereira Brian JG

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON SALEM NORTH CAROLINA 27103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$1.81	05/28/2026		A		135,000(1)		(2)	05/28/2036	Class A Common Stock	135,000	$0	135,000	D

Explanation of Responses:

1. These options were granted under the Issuer's non-employee director compensation policy.

2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

	/s/ Todd Girolamo, attorney in fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PROKIDNEY CORP. (PROK) director Brian JG Pereira report on this Form 4?

Brian JG Pereira reported receiving a grant of 135,000 director stock options. These options were issued under PROKIDNEY CORP.’s non-employee director compensation policy and relate to Class A common stock, reflecting a compensation award rather than an open-market transaction.

How many stock options did PROK director Brian JG Pereira receive and at what exercise price?

He received 135,000 director stock options with an exercise price of $1.81 per share. These options give him the right to buy PROKIDNEY CORP. Class A common stock at that price if the options vest and are exercised in the future.

When do Brian JG Pereira’s newly granted PROK stock options vest?

The options will vest in full on the earlier of the one-year anniversary of the grant date or PROKIDNEY CORP.’s next annual general shareholder meeting. This structure is typical for non-employee director compensation plans and ties vesting to ongoing board service.

What is the expiration date of the PROK stock options granted to director Brian JG Pereira?

These director stock options expire on May 28, 2036. After that date, any unexercised options will lapse. The long duration provides an extended window for potential exercise, consistent with common equity incentive practices for non-employee directors.

Are Brian JG Pereira’s reported PROK transactions open-market buys or compensation awards?

The filing describes the transaction as a grant or award acquisition, not an open-market purchase. Footnotes confirm the options were granted under PROKIDNEY CORP.’s non-employee director compensation policy, indicating standard director equity compensation rather than discretionary trading activity.

How many PROK stock options does Brian JG Pereira hold after this reported grant?

Following this grant, his reported holdings for this award total 135,000 director stock options. This figure represents options associated with this specific grant, tied to Class A common stock, and reflects his position as disclosed in the Form 4 filing.